Coherus BioSciences

Coherus BioSciences

Develops and commercializes biosimilars for healthcare

About Coherus BioSciences

Simplify's Rating
Why Coherus BioSciences is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Overview

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. Coherus's mission is to improve patient lives by expanding access to these essential treatments, helping to offset rising healthcare costs. The company serves healthcare providers, hospitals, and patients, focusing on rigorous research and development to ensure their products meet high quality and efficacy standards. By providing cost-effective alternatives to original biologics, Coherus creates a competitive advantage in the biopharmaceutical market, driving sales and profitability while enhancing healthcare accessibility.

šŸ“ˆ
Significant Headcount Growth
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on immuno-oncology enhances pipeline and market position.
  • Launch of Udenyca wearable injector device improves drug delivery systems.
  • Strategic collaborations could lead to new partnerships and investment opportunities.

What critics are saying

  • Exit from biosimilar space may lead to loss of market share.
  • 30% staff reduction could affect innovation and productivity.
  • Collaboration with Cancer Research Institute may face scientific and regulatory hurdles.

What makes Coherus BioSciences unique

  • Focus on biologic therapeutics for oncology and inflammatory diseases.
  • Expertise in process science and analytical characterization.
  • Commitment to high-quality, cost-effective biosimilars.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$950.7M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

↑ 5%

1 year growth

↑ 5%

2 year growth

↑ 5%
PharmiWeb
May 28th, 2025
Storm Therapeutics Announces First Patient Dosed In Clinical Collaboration To Evaluate Stc-15 In Combination With LoqtorziĀ® And Appointment Of Atif Abbas, M.D., As Chief Medical Officer

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZIĀ® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor

Fierce Pharma
Apr 23rd, 2025
Coherus loses commercial chief amid exit from biosimilar space

Coherus hired Sameer Goregaoker as senior VP of immuno-oncology marketing and Loqtorzi brand lead late last year.

ETF Daily News
Mar 29th, 2025
Intech Investment Management LLC Makes New $38,000 Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Intech Investment Management LLC makes new $38,000 investment in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Stock Titan
Feb 24th, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference.

PE Hub
Jul 3rd, 2024
SK Capital's Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.

Recently Posted Jobs

Sign up to get curated job recommendations

Coherus BioSciences is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

šŸ’”
We update Coherus BioSciences's jobs every few hours, so check again soon! Browse all jobs →